Health Vision Enterprise executes exclusive marketing agreement with Shanghai RAAS for their innovative haemostatic product, FibinGluRAAS®, a dual syringe containing fibrinogen and thrombin
Health Vision Enterprise Ltd signed a Cooperation Agreement with Shanghai RAAS Blood Products Co., LTD for the exclusive marketing rights of FibinGlu®, a plasma derived fibrin sealant used for haemostasis in surgery.
Shanghai RAAS Blood Products Co., Ltd., started as a joint venture between US RAAS (Rare Antibody Antigen Supply) and Shanghai Blood Center, owned by Public Health of Shanghai, which was established in 1988. In 2004 the investing company Creat Group acquired Shanghai Blood Center and became the new partner.
"FibinGlu is a wide range topical sealant for surgery. RAAS is the brand leader in Blood Product field," stated Health Vision Managing Director Alex Leung. He said: "We believe that the sales of Fibrin Sealant will come to a new level in China. Shanghai RAAS Blood Products Co., LTD has selected HVE because of our track record of distributing high-quality products and the professionalism of our sales team."
April 28, 2007 – Nan Jing, China
Obtain business license for Health Vision (Nan Jing) Medicine company, a wholly foreign owned enterprise allowing importation, logistic distribution and licensing-in products
Health Vision Medicine (Nan Jing) Co., Ltd was established today. It is one of the earliest established wholly foreign owned pharmaceutical distribution companies licensed in the Peoples Republic of China. It will serve as a logistic platform for Health Vision's products and as well enable the Health Vision Group to take on exclusive distribution rights for locally manufactured products.
"This is a very important landmark event for Health Vision Enterprise (HVE)," said Zona Yim, Managing Director for HVE. "Health Vision Medicine (Nan Jing) Co., Ltd. has successfully obtained all business licenses and starts operation," she said. "This permits us to increase our services and capabilities and expand our pharmaceutical distribution platform in the PRC."
October 28, 2007 – Nan Jing, China
Health Vision (Nan Jing) Medicine Company Limited obtains GSP license
Health Vision Medicine (Nan Jing) Co., Ltd, a wholly foreign owned medicine company obtains GSP license today. It makes Health Vision the 3rd foreign company in China to obtain a GSP license. The GSP license allows us to license-in locally manufactured products, thus further strengthening our product portfolio and HV infrastructure.
July 30, 2008 – Tokyo, Japan
Health Vision Enterprise appoints Eisai China Inc. as the marketing agent for Alpha Lipon®, a company with a focus in endocrinology
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that Eisai China Inc. (Headquarters: Suzhou, President: Yukio Akada, "ECI"), a whollyowned subsidiary of Eisai Co., Ltd., has entered into license agreement with Health Vision Enterprise Ltd. (Headquarters: Hong Kong, Directors: Alex Leung and Zona Yim, "Health Vision"), a sales subsidiary of STADA Arzneimittel AG (Headquarters: Germany, "STADA"), for sales and repack of α-Lipon 300 STADAⓇ (generic name: α-lipoic acid) in China. α- Lipon 300 STADAⓇ is a treatment for diabetic neuropathic pain developed by STADA.
With this agreement, ECI will take over sales promotion activities for α-Lipon 300 STADAⓇ in China from Health Vision from August 1. Health Vision will establish marketing strategies, coordinate importation and regulatory affairs. Both parties express strong confidence that the cooperation will facilitate a faster access to the Chinese market.
α-Lipon 300 STADAⓇ is a therapeutic agent for diabetic neuropathic pains developed by STADA, and has been on the market in China since 2005. It relieves neuropathic pain associated with diabetes by its antioxidant effect, which reduces overproduction of oxygen species and normalization of glucose metabolism.
Recently, the incidence of diabetes in China has been increasing by about 10% every year, as part of a result of rapid economic growth. Currently, it is estimated that there are more than 30 million patients with diabetes and the number is expected to reach 46 millions in 2025. Diabetic neuropathy is one of the common complications associated with diabetes and may lead to paresthesia, which causes problems such as pain or numbness in the end of the fingers and toes. α-Lipon 300 STADAⓇ is used to treat these symptoms.
<< Click here for more >>
 |
|
|